Retrospective survival analysis of patients with small bowel neuroendocrine tumors (NETs) and analysis of patient satisfaction post covid pandemic in the Sheffield European Neuroendocrine Tumor Society (ENETS) Centre of Excellence (COE)

#3628

Introduction: Small bowel NETs are the commonest primary malignancies of the small bowel. Incidence is increasing, but it is often still diagnosed at a late stage. The effects of COVID-19 may have affected patient satisfaction. Reported survival is quoted at 90% at 1 year and 70% at 5 years for all stages.

Aim(s): To identify patients with small bowel NETs being treated by Sheffield ENETS COE, calculate overall 1- and 5-year survival and perform a NET patient satisfaction survey post COVID.

Materials and methods: The NET database was analysed between 2015 and 2022 date. 111 patients satisfied inclusion criteria. Survival rates were calculated at 1 and 5 years and Kaplan-Meier graphs were plotted. A 40 MCQ postal survey was created including questions regarding psychological support and COVID-19.

Conference:

Presenting Author:

Authors: Kwok W, Finnen J, Munir A,

Keywords: Neuroendocrine, cell, research, Neuroendocrine tumor, Survival analysis, patient satisfaction,